4a IR ύ (cm-1): 3325 (NH); 2967(-CH); 1671 (C=O); 1609 (C=N) and 1243 (C=S). (ppm): 1.89-1.96 (pentet, 2H, CH ); 2.64-2.88 (m, 4H, 2CH ); 7.97 (s, 1H, pyrimidine HC=N); 8.11 (s, 1H, pyrimidine HC=CO) and 8.92 (s, 1 H , H 2 2 1H NMR δ NH ). Mass (m/z): 221 (M.+ +2, 6.6%); 219 (M+., 100.0%); 161 (34.8 %); 131 (14.5%); 104 (19.6%) and 77 (18.8%).
4b IR ύ (cm-1): 3390 (NH); 2936 (-CH); 1658 (C=O); 1624 (C=N) and 1255 (C=S). 1H NMR δH (ppm): 1.24-1.72 (m, 4H, 2CH2); 2.60-2.81 (m, 4H, 2CH2); 7.97 (s, 1H, pyrimidine HC=N); 8.14 (s, 1H, pyrimidine HC=CO) and 12.10 (s, 1H, SH) Mass (m/z): 235 (M.+ +2, 6.7%); 233 (M+., 100.0%); 175 (18.1 %); 143 (31.7%); 119 (15.8%) and 68 (25.2%).
4c IR ύ (cm-1): 3400 (NH); 2927 (-CH); 1680 (C=O); 1613 (C=N) and 1245 (C=S). 1H NMR δ H (ppm): 1.29-1.67 (m, 4H, 2CH 2 ); 2.42-2.92 (m, 4H, 2CH 2 ); 3.22-3.41 (m, 4H, 2CH 2 ), 7.99 (s, 1H, pyrimidine N=C-H); 8.01 (s, 1H, pyrimidine O=C=CH) and 12.91 (br s, 1H, SH) Mass (m/z): 261 (M+., 100.0%); 323 (15.0%); 173 (7.4%); 103 (3.6%) and 77 (11.8%).
4d IR ύ (cm-1): 3352 (NH); 2923 (-CH); 1679 (C=O); 1621 (C=N) and 1246 (C=S). Mass (m/z): 319 (M.+ +2, 19.8%); 317 (M+., 94.0%); 246 (25.5 %); 207 (100.0%); 147 (21.2%) and 91 (19.0%).
8 IR ύ (cm-1): 3368 (NH); 2970 (-CH); 1627 (C=O); 1591 (C=N) and 1243 (C=S). 1H NMR δH (ppm): 1.44 (s, 3H, CH3); 8.00 (s, 1H, pyrimidine N=C-H); 8.16 (s, 1H, pyrimidine C=CH); 8.26 (s, 1H, pyrimidine HC=C=O and 12.87 (s, 1H, SH). Mass (m/z): 193 (M.+, 37.4%); 189 (100.0%); 161 (25.2%); 91 (20.3%); and 75 (42.3%).
10 IR ύ (cm-1): 3325 (NH); 2970 (-CH); 1630 (C=O); 1592 (C=N) and 1243 (C=S). 1H NMR δ (ppm): 6.89-7.89 (m, 5H, Ar); 8.10 (s, 1H, pyrimidine N=C-H); 8.21 (s, 1H, pyrimidine C=CH); 8.26 (s, 1H, pyrimidine HC=C=O and 12.68 (s, 1H, H SH). Mass (m/z): 255 (2.9%); 151 (65.5); 95 (81.5%); 80 (17.3 %) and 67 (100.0).
Table 2: The spectral data of the newly synthesized compounds 4a-d, 8 and 10.